Fig 4.
New requirement for insulin for ≥30 days in previously non-diabetic participants. *Trial Miller 2002 is largely responsible for the heterogeneity among trials at one year. Sensitivity analysis showed a relative risk of 2.19 (1.42 to 3.38), and much reduced heterogeneity (P=0.18, I2=27.5%) when this trial was removed from the analysis
